N. Ishii

发表

Establishment and characterization of an androgen receptor‐dependent, androgen‐independent human prostate cancer cell line, LNCaP‐CS10

Ayako Nishimoto, Nobuyuki Ishikura, H. Kawata, 2010, The Prostate.

Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment

K. Nagano, S. Morimoto, T. Shinkawa, 2009, Proteomics.

Integration of proteomic analyses to monitor the activity status of phosphorylation signaling.

S. Nagahashi, N. Yabuki, K. Nagano, 2011, Journal of proteomics.

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

S. Mu, R. Rueger, P. Goelzer, 2009, Clinical Cancer Research.

Cancer Therapy : Clinical The Safety , Tolerability , Pharmacokinetics , and Pharmacodynamics of Single Oral Doses of CH 4987655 in Healthy Volunteers : Target Suppression Using a Biomarker

S. Mu, R. Rueger, P. Goelzer, 2009 .

Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.

M. Ohmori, Hiroki Nishii, K. Morikami, 2016, Journal of medicinal chemistry.

AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results

K. Flaherty, M. Voss, G. Iyer, 2019, Hepatobiliary surgery and nutrition.

Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor‐D

K. Kashima, J. Hata, N. Ishii, 2012, Cancer science.

Synthesis and structure-activity relationships of novel benzofuran farnesyltransferase inhibitors.

M. Sakaitani, T. Fukami, N. Shimma, 2009, Bioorganic & medicinal chemistry letters.

Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor.

M. Voss, R. Heist, J. Supko, 2015 .

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

Hiroshi Sakamoto, H. Sakamoto, T. Fukami, 2011, Cancer cell.

A signature-based method for indexing cell cycle phase distribution from microarray profiles

Hideaki Mizuno, Yoshito Nakanishi, Akinori Sarai, 2009, BMC Genomics.

Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells

N. Yanaihara, A. Okamoto, Tadao Tanaka, 2005, Clinical Cancer Research.

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

Miyuki Yoshida, N. Ishii, Y. Aoki, 2011, Clinical Cancer Research.

Cancer Therapy : Preclinical The Selective Class I PI 3 K Inhibitor CH 5132799 Targets Human Cancers Harboring Oncogenic PIK 3 CA Mutations

Miyuki Yoshida, N. Ishii, Y. Aoki, 2011 .

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Christof Fellmann, Scott Lowe, Neal Rosen, 2014, Cancer cell.

Isolation and characterization of Candida albicans homologue of RAP1, a repressor and activator protein gene in Saccharomyces cerevisiae.

R. Haw, H. Uemura, N. Ishii, 2004, Yeast.

Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma

N. Yanaihara, A. Okamoto, T. Akiyama, 2015, PloS one.

YES1 is a targetable oncogene in cancers harboring YES1 gene amplification.

H. Koyano, N. Ishii, Haruhiko Sato, 2019, Cancer research.

Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non‐small‐cell lung cancer

N. Ishii, Y. Aoki, O. Kondoh, 2013, Cancer science.

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1

M. Aoki, N. Ishii, T. Tsukaguchi, 2015, Molecular Cancer Therapeutics.

Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.

N. Rosen, T. Sakai, M. Arisawa, 2013, Cancer research.

Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer

M. Aoki, N. Ishii, T. Mio, 2018, Molecular Cancer Therapeutics.

A Novel Mechanism of EML4-ALK Rearrangement Mediated by Chromothripsis in a Patient-Derived Cell Line

Y. Ishikawa, K. Kitada, H. Sakamoto, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

Li Lu, Michael Pawlak, Jean Tessier, 2014, EJNMMI Research.

ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor

M. Aoki, N. Ishii, Y. Aoki, 2015, Molecular Cancer Therapeutics.

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

K. Morikami, H. Shindoh, N. Ishii, 2014, Molecular Cancer Therapeutics.

Small Molecule Therapeutics The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH 5183284 / Debio 1347 , a Novel Selective FGFR Inhibitor

K. Morikami, H. Shindoh, N. Ishii, 2014 .

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

A. Iafrate, K. Flaherty, J. Baselga, 2019, Clinical Cancer Research.

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

V. Seshan, S. Larson, N. Rosen, 2016, The Journal of clinical investigation.

Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC).

K. Flaherty, J. Baselga, M. Voss, 2018 .

Indoleamine 2 , 3-Dioxygenase Serves as aMarker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells

N. Yanaihara, A. Okamoto, Tadao Tanaka, 2005 .

Ido serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

N. Yanaihara, A. Okamoto, Tadao Tanaka, 2007 .

Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor-4

K. Kashima, J. Hata, N. Ishii, 2014, Cancer science.

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)‐overexpressing cancers

Shigeo Sato, N. Ishii, Y. Aoki, 2012, Cancer science.

Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.

K. Flaherty, J. Baselga, M. Voss, 2017 .

[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models

S. Stone-Elander, P. Pisa, J. Tessier, 2013, EJNMMI Research.

Identification of a Novel Vascular Endothelial Growth Factor Receptor 2 Inhibitor and Its Effect for Choroidal Neovascularization In Vivo

R. Obata, Y. Inoue, Y. Tamaki, 2008, Current eye research.